Talazoparib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Talazoparib
Talazoparib: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Talazoparib, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| breast neoplasms | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 14683T | Talzenna | Capsule 500 micrograms (as tosilate) | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (PARP inhibitor with PARP-trapping activity) |
| Myelosuppression Risk | Please refer to the Product Information (PI). Thrombocytopenia and other cytopenias are recognised concerns with this drug class. |
| Emetogenicity Classification | Please refer to the Product Information (PI) |
| Monitoring Items | Full blood count, and liver and renal function. Confirm the schedule against the PI. |
| Handling Protection | Please refer to the Product Information (PI) and local cytotoxic drug handling guidance |
Safety Considerations
Warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Drug Interactions: The interaction query returned 100 entries. The first 20 reviewed include:
- Major: clarithromycin, deferiprone, samarium (153Sm) lexidronam
- Moderate: eliglustat, eluxadoline, rolapitant, simvastatin, fidaxomicin, cobicistat, palifermin, strontium chloride Sr-89, eltrombopag, fostamatinib, ticagrelor, quinine, ivacaftor, roflumilast, chloramphenicol (including ophthalmic), erythromycin
The full list should be reviewed against the PI before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.